Investigating new immunotherapy options for osteosarcoma
Official title: Exploration of different immunotherapy modalities in osteosarcoma
Funded at Auburn University at Auburn · NIH-10730833 · Data updated 2026-11-12
This study is looking at new ways to help the immune system fight osteosarcoma, a type of bone cancer, by using special treatments like CAR T cells and oncolytic viruses, with the goal of making things better for patients dealing with this condition.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Auburn University at Auburn NIH-funded |
| Lab location | 1 site (Auburn, UNITED STATES) |
| Project start | July 5, 2023 |
| Project end | June 30, 2026 |
| Funding year | 2023 |
| Award (this year) | $440,640 |
| NIH project number | 1R15CA283777-01 |
| Project ID | NIH-10730833 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with osteosarcoma, particularly those who have not responded well to existing treatments.
✕Less likely to help
Patients with osteosarcoma who are in advanced stages and have exhausted all treatment options may not benefit from this research.
What this research studies
This research explores innovative immunotherapy approaches for treating osteosarcoma, a common bone cancer in both children and adults. The study focuses on using chimeric antigen receptor (CAR) T cells and immune checkpoint inhibitors, such as monoclonal antibodies, to enhance the immune response against tumor cells. Additionally, it examines the use of oncolytic viruses that can specifically target tumor cells and stimulate the immune system within the tumor microenvironment. By combining these strategies, the research aims to improve treatment outcomes for patients with osteosarcoma.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for osteosarcoma, potentially improving survival rates and quality of life for patients.
How similar studies have gone: Previous research has shown promise in using immunotherapy for various cancers, indicating potential success for similar approaches in osteosarcoma.
Where this research is happening
-
Auburn University at Auburn
Auburn, United States Active
Researchers
- Principal investigator: Agarwal, Payal — Auburn University at Auburn
- Study coordinator: Agarwal, Payal
Related research
Other NIH-funded projects on the same topics.
-
Using engineered natural killer cells to treat bone cancer
This study is testing a new treatment for bone cancer called osteosarcoma by using specially modified immune cells that can better find and kill cancer cells, aiming to offer a safer and more effective option for patients.
-
Using MRI to guide cryotherapy and deliver immune therapy for treating canine osteosarcoma
This study is testing a new way to treat osteosarcoma in dogs by using a special cooling technique to freeze the tumor and then giving an injection to help the dog's immune system fight any leftover cancer cells, all to help improve the health of dogs with this tough cancer.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.